Key references: Nonresponse to initial pharmacotherapy for generalised anxiety disorder in adults and young people

  • Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 2014;28(5):403–39. https://www.ncbi.nlm.nih.gov/pubmed/24713617
  • Baldwin DS, den Boer JA, Lyndon G, Emir B, Schweizer E, Haswell H. Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature. J Psychopharmacol 2015;29(10):1047–60. https://www.ncbi.nlm.nih.gov/pubmed/26259772
  • Bandelow B, Reitt M, Rover C, Michaelis S, Gorlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol 2015;30(4):183–92. https://www.ncbi.nlm.nih.gov/pubmed/25932596
  • Buoli M, Caldiroli A, Serati M. Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder. Expert Opin Drug Metab Toxicol 2017;13(3):351–9. https://www.ncbi.nlm.nih.gov/pubmed/28075650
  • Buoli M, Grassi S, Serati M, Altamura AC. Agomelatine for the treatment of generalized anxiety disorder. Expert Opin Pharmacother 2017;18(13):1373–9. https://www.ncbi.nlm.nih.gov/pubmed/28730851
  • Cvjetkovic-Bosnjak M, Soldatovic-Stajic B, Babovic SS, Boskovic K, Jovicevic M. Pregabalin versus sertraline in generalized anxiety disorder. An open label study. Eur Rev Med Pharmacol Sci 2015;19(11):2120–4. https://www.ncbi.nlm.nih.gov/pubmed/26125277
  • Gomez AF, Barthel AL, Hofmann SG. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. Expert Opin Pharmacother 2018;19(8):883–94. https://www.ncbi.nlm.nih.gov/pubmed/29806492
  • Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 2014;14 Suppl 1:S1. https://www.ncbi.nlm.nih.gov/pubmed/25081580
  • Maneeton N, Maneeton B, Woottiluk P, Likhitsathian S, Suttajit S, Boonyanaruthee V, et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther 2016;10:259–76. https://www.ncbi.nlm.nih.gov/pubmed/26834458
  • Molero Y, Larsson H, D'Onofrio BM, Sharp DJ, Fazel S. Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden. BMJ 2019;365:l2147. https://www.ncbi.nlm.nih.gov/pubmed/31189556
  • Montgomery SA, Lyndon G, Almas M, Whalen E, Prieto R. Early improvement with pregabalin predicts endpoint response in patients with generalized anxiety disorder: an integrated and predictive data analysis. Int Clin Psychopharmacol 2017;32(1):41–8. https://www.ncbi.nlm.nih.gov/pubmed/27583543
  • National Institute for Health and Care Excellence (NICE). Generalised anxiety disorder and panic disorder in adults: management [CG113]. London: NICE; 2011 (updated 2019). https://www.nice.org.uk/guidance/CG113
  • Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003;160(3):533–40. https://www.ncbi.nlm.nih.gov/pubmed/12611835
  • Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet 2019;393(10173):768–77. https://www.ncbi.nlm.nih.gov/pubmed/30712879
  • Stein DJ, Ahokas A, Jarema M, Avedisova AS, Vavrusova L, Chaban O, et al. Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study. Eur Neuropsychopharmacol 2017;27(5):526–37. https://www.ncbi.nlm.nih.gov/pubmed/28298261